SCHEMBL14859888

SCHEMBL14859888

CC(C)(C)c1ccc(C(=O)N(S)C(=O)NCc2cccc(Cl)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 5/20 0.51
▸ KMT2A Q03164 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ LMNA P02545 4/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ EPHX2 P34913 2/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAPGEF3 O95398 1/20 0.44
▸ RAPGEF4 Q8WZA2 1/20 0.44
▸ HTT P42858 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CXCR3 P49682 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14859138 0.87 NR1H4 (0.52) NR1H4KMT2AMEN1LMNARAB9A
SCHEMBL14860301 0.86 MEN1 (0.67) NR1H4KMT2AMEN1CYP1A2CYP2C19
SCHEMBL14859532 0.82 NR1H4 (0.50) NR1H4KMT2AMEN1CYP1A2CYP2C19
SCHEMBL14860477 0.80 KCNK9 (0.50) NR1H4KMT2AMEN1LMNARAB9A
SCHEMBL14860316 0.80 EPHX2 (0.59) NR1H4KMT2AMEN1CYP1A2CYP2C19
SCHEMBL14860245 0.79 EPHX2 (0.54) NR1H4KMT2AMEN1CYP1A2CYP2C19
SCHEMBL14860029 0.77 CNR1 (0.52) NR1H4KMT2AMEN1LMNARAB9A
SCHEMBL14859887 0.77 ALDH1A1 (0.65) NR1H4KMT2AMEN1CYP1A2CYP2C19
SCHEMBL14859225 0.76 RAB9A (0.67) NR1H4LMNARAB9AEPHX2NPC1
SCHEMBL14859489 0.76 RAB9A (0.56) KMT2ACYP2C19LMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP claimed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US claimed
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP disclosed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT UGP2, TPMT, UPP1 NR1H4 4314/4885KMT2A 2604/4885MEN1 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback